LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of the 26th day of March, 2007 (the “Effective Date”), is entered into by and between BAYER SCHERING PHARMA AG (formerly known as SCHERING AG), a German corporation, with a place of business at Muellerstrasse 178, Berlin 13342, Germany (“Bayer”) and SYNDAX PHARMACEUTICALS, INC., a Delaware corporation, with a place of business at 12481 High Bluff Drive, Suite 150, San Diego, California 92130 (“Licensee”). Bayer and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN NANOBIOTIX S.A. AND LIANBIO ONCOLOGY LIMITEDLicense, Development and Commercialization Agreement • April 8th, 2022 • Nanobiotix S.A. • Pharmaceutical preparations
This License, Development and Commercialization Agreement (this “Agreement”) is entered into and effective as of May 11, 2021 (the “Effective Date”), by and between Nanobiotix S.A., a French société anonyme having its registered office located at 60 Rue de Wattignies, 75012, Paris, France, registered under number 447 521 600 (RCS Paris) (“Nanobiotix”), and LianBio Oncology Limited, a Hong Kong company limited by shares, having its principal place of business located at Room 1902, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong ( “Lian”). Nanobiotix and Lian are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO THE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT (this “Amendment”) to the License, Development and Commercialization Agreement (as hereinafter defined), is effective as of the 1st day of February 2013 (the “Second Amendment Effective Date”), by and between Bayer Pharma AG (formerly known as Bayer Schering Pharma AG), a German corporation, with a place of business at Muellerstrasse 178, Berlin 13342, Germany (“Bayer”), and Syndax Pharmaceuticals, Inc., a Delaware corporation, with a place of business at 460 Totten Pond Road, Suite 650, Waltham, Massachusetts 02451, USA (“Licensee”).
ANDLicense, Development and Commercialization Agreement • April 7th, 2006 • Vanda Pharmaceuticals Inc. • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...License, Development and Commercialization Agreement • September 13th, 2016 • AC Immune SA • Pharmaceutical preparations
This license, development and commercialization agreement (this “Agreement”) is dated December 24, 2014 and is between Janssen Pharmaceuticals, Inc., a Pennsylvania company (“Janssen”) and AC Immune SA, a Swiss company (“ACI”).
BACKGROUNDLicense, Development and Commercialization Agreement • January 30th, 2007 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between ECHO THERAPEUTICS, INC. and MEDICAL TECHNOLOGIES INNOVATION ASIA, LTD.License, Development and Commercialization Agreement • May 1st, 2014 • Echo Therapeutics, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of December 9, 2013 (the “Effective Date”), by and between Echo Therapeutics, Inc., having offices at 8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 USA (“Echo”), and Medical Technologies Innovation Asia, Ltd., having registered offices at RM8, 17/F, Block B, Vigor Industrial Building, 14-20, Cheung Tat Road, Tsing Yi, Hong Kong (“MTIA”).
CONFIDENTIAL LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between MERSANA THERAPEUTICS, INC. and RECEPTA BIOPHARMA S.A.License, Development and Commercialization Agreement • June 1st, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
This License, Development and Commercialization Agreement (“Agreement”), effective as of July 9, 2015 (“Effective Date”), is by and between Mersana Therapeutics, Inc. (“Mersana”), with offices at 840 Memorial Dr., Cambridge, MA 02139, USA and Recepta Biopharma, S.A. (“Recepta”), with offices at Rua Tabapuã, 1123 conj 36, Itaim Bibi, São Paulo, SP, CEP 04533 - 014, Brazil. Mersana and Recepta may be referred to in this Agreement individually as a “Party” or together as the “Parties.”
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED “[***]” BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by...License, Development and Commercialization Agreement • March 1st, 2021 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of February 28, 2007 by and between BIOCRYST PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware having offices at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (“BioCryst”), and SHIONOGI & CO., LTD., a corporation organized and existing under the laws of the Japan having offices at 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan (“Shionogi”). BioCryst and Shionogi are each referred to herein by name or individually as a “Party” or collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • September 8th, 2017 • Array Biopharma Inc • Pharmaceutical preparations • New York
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) dated as of May 31, 2017 (the “Effective Date”), is made and entered into by and between Array BioPharma Inc., a company organized under the laws of Delaware and having its principal place of business at 3200 Walnut Street, Boulder, CO 80301 USA, (“Array”) and Ono Pharmaceutical Co., Ltd., a company duly organized and existing under the laws of Japan, having offices and principal place of business at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan (“Ono”).
TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • March 26th, 2024 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT #8 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("AD Pharma"), a Kentucky limited liability company, having a place of business at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of March 15, 2024.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between ALLOS THERAPEUTICS, INC., a Delaware corporation and MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED a Bermuda corporationLicense, Development and Commercialization Agreement • August 4th, 2011 • Allos Therapeutics Inc • Pharmaceutical preparations • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AMYLIN PHARMACEUTICALS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED: OCTOBER 30, 2009License, Development and Commercialization Agreement • February 26th, 2010 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
The Co-Commercialization Agreement shall include the following terms and conditions, unless otherwise mutually agreed by the Parties, in addition to such terms and conditions as are customarily contained in similar agreements in the pharmaceutical industry and such other terms and conditions as the Parties may agree upon:
AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • March 31st, 2021 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT (the “Amendment”) to the LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky partnership having a place of business at with offices at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of October 16, 2020.
AMENDMENT N°. 1 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“AMENDMENT N°. 1”) by and between WINDTREE THERAPEUTICS, INC. and LEE’S PHARMACEUTICAL (HK) LTD.License, Development and Commercialization Agreement • November 14th, 2017 • Windtree Therapeutics Inc /De/ • Biological products, (no disgnostic substances)
Effective as of August 14, 2017, Windtree Therapeutics, Inc. (“Licensor”) and Lee’s Pharmaceutical (HK) Ltd. (“Licensee”) hereby agree to amend the License, Development and Commercialization Agreement between them dated as of June 12, 2017 (the “Agreement”) in consideration of Licensee lending to Licensor the amount of Three Million, Nine Hundred Thousand Dollars ($3,900,000) in cash (“Bridge Loan”), which loan shall be subject to and payable in accordance with the terms of the Loan Agreement between the Parties dated of even date herewith. Capitalized terms used herein not otherwise defined shall have the meanings ascribed to them in the Agreement.
AMENDMENT #6 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • June 28th, 2023 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT #6 (this “Amendment”) TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, having a place of business at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of June 15, 2023.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BAYER CONSUMER CARE AG and LOXO ONCOLOGY, INC. November 14, 2017License, Development and Commercialization Agreement • March 1st, 2018 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of November 14, 2017 (the “Effective Date”) by and between:
AMENDMENT #2 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • June 30th, 2023 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT (the “Amendment #2”) to the LICENSE, DEVELOPMENT and COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky partnership having a place of business at with offices at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of June 17, 2021.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE, DEVELOPMENT AND COMMERCIALIZATION...License, Development and Commercialization Agreement • October 11th, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This License, Development and Commercialization Agreement (this “Agreement”), effective as of September 16, 2015 (the “Execution Date”), is made by and between Armetheon, Inc., a Delaware corporation with place of business at 490 N. McCarthy Blvd., Suite 200, Milpitas, California 95035 (“Licensor”), and China Cardiovascular Focus Ltd., a company organized under the laws of the British Virgin Islands (Company nr. 1646310) whose principal place of business is at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong (“Licensee”), a wholly-owned Affiliate of Lee’s Pharmaceutical Holdings Ltd. Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Treatment Requested Confidential portions of this document have been redacted and have been separately filed with the Commission LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and...License, Development and Commercialization Agreement • November 9th, 2009 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made and entered into as of June 11, 2004 between VERTEX PHARMACEUTICALS INCORPORATED (hereinafter “VERTEX”), a Massachusetts corporation with principal offices at 130 Waverly Street, Cambridge, MA 02139-4242, and MITSUBISHI PHARMA CORPORATION (hereinafter “MITSUBISHI”), a Japanese corporation with principal offices at 6-9, Hiranomachi 2-Chome, Chuo-ku, Osaka 541-0046, Japan. VERTEX and MITSUBISHI are sometimes referred to herein individually as the “Party” and collectively as the “Parties”.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF MARCH 31, 2015 BY AND BETWEEN BRICKELL BIOTECH, INC. AND KAKEN PHARMACEUTICAL CO., LTD.License, Development and Commercialization Agreement • September 3rd, 2019 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This License, Development and Commercialization Agreement (this “Agreement”), dated as of March 31, 2015 (the “Effective Date”), is made by and between Brickell Biotech, Inc., a Delaware corporation (“Brickell”) and Kaken Pharmaceutical Co. Ltd., a company legally organized and existing under the laws of Japan (“Kaken”). Brickell and Kaken are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • March 31st, 2020 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This License, Development and Commercialization Agreement (“Agreement”) is made and entered into as of June 28, 2019 (the “Effective Date”) by and between Abuse Deterrent Pharmaceuticals, LLC, with offices at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202 (“AD Pharma”), and Acura Pharmaceuticals, Inc., with offices at 616 N. North Court, Palatine IL 60067 (“Acura”). AD Pharma and Acura each are referred to herein as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • November 16th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations
This License, Development and Commercialization Agreement (this “Agreement”) is entered into as of this 10th day of October, 2020, (the “Effective Date”) by and between
Exhibit A-1 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • August 9th, 2006 • Myogen Inc • Pharmaceutical preparations • Massachusetts
This License, Development and Commercialization Agreement (this “Agreement”) is made this day of , 200___ by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 West 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between ALLOS THERAPEUTICS, INC., a Delaware corporation and MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED a Bermuda corporationLicense, Development and Commercialization Agreement • March 26th, 2012 • Allos Therapeutics Inc • Pharmaceutical preparations • New York
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTLicense, Development, and Commercialization Agreement • June 1st, 2007 • Novacea Inc • Pharmaceutical preparations • Delaware
This License, Development, and Commercialization Agreement (this “Agreement”) is entered into as of the Effective Date by and between NOVACEA, Inc., a Delaware corporation having offices at 601 Gateway Blvd., Suite 800, South San Francisco, California 94080 (“Novacea”), and Schering Corporation, a New Jersey corporation having offices at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (“Schering”).
AMENDMENT # 1 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • February 22nd, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment # 1 to LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Amendment”), is entered into between Syndax Pharmaceuticals, Inc., a Delaware corporation having a place of business at 400 Totten Pond Road, Suite 110, Waltham, MA 02451 USA (“Syndax”) and Kyowa Hakko Kirin Co., Ltd., a Japanese corporation having a place of business at 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185, Japan (“KHK”).
AMENDMENT #4 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • December 27th, 2022 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT #4 (this “Amendment”) TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) dated June 28, 2019 between Acura Pharmaceuticals, Inc. (“Acura”), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC (“AD Pharma”), a Kentucky limited liability company, having a place of business at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of November 10, 2022.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • November 9th, 2018 • Synergy Pharmaceuticals, Inc. • Pharmaceutical preparations • Hong Kong
This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of August 3, 2018 (the “Effective Date”) by and between SYNERGY PHARMACEUTICALS INC., a corporation organized and existing under the laws of Delaware and having a place of business at 420 Lexington Avenue # 2012, New York, NY 10170, USA (“Synergy”) and SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., a corporation organized and existing under the laws of the People’s Republic of China and having a place of business at Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province (“Luoxin”). Synergy and Luoxin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between LUNG BIOTECHNOLOGY PBC and COLLPLANT LTD. Dated as of October 19, 2018License, Development and Commercialization Agreement • October 25th, 2018 • CollPlant Holdings Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • Delaware
This License, Development and Commercialization Agreement (this “Agreement”) is dated as of October 19, 2018 (the “Execution Date”), by and between CollPlant Ltd. (“CollPlant”), a company organized and existing under the laws of Israel and having its principal place of business at 3 Sapir Street, Weizmann Science Park, P.O.B. 4132, Ness-Ziona 74140, Israel, and Lung Biotechnology PBC (“LB”), a public benefit corporation and wholly-owned subsidiary of United Therapeutics Corporation, a company organized and existing under the laws of the State of Delaware, U.S.A., and having its principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910, U.S.A. (each of CollPlant and LB individually referred to as a “Party” and collectively as the “Parties”).
SECOND AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • September 18th, 2009 • Cardica Inc • Surgical & medical instruments & apparatus
THIS SECOND AMENDMENT (“Second Amendment”) to the License, Development and Commercialization Agreement dated 12th of June, 2007 (“Agreement”) by and between Cook Incorporated and its Affiliates (“Cook”), and Cardica, Inc., and its Affiliates (“Cardica”) is made by and between the same two parties on this 19th day of June, 2009 (“Second Amendment Effective Date”). The parties agree as follows:
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AMAG PHARMACEUTICALS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED MARCH 31, 2010License, Development and Commercialization Agreement • May 6th, 2010 • Amag Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • New York
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF SEPTEMBER 7, 2010 BY AND AMONG ONYX PHARMACEUTICALS, INC. AND ONYX THERAPEUTICS, INC. AND ONO PHARMACEUTICAL CO., LTD.License, Development and Commercialization Agreement • November 3rd, 2010 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This License, Development and Commercialization Agreement (this “Agreement”), dated as of September 7, 2010 (the “Effective Date”), is made by and among Onyx Pharmaceuticals, Inc., a Delaware corporation, and Onyx Therapeutics, Inc., a Delaware corporation (together referred to as, “Onyx”), and Ono Pharmaceutical Co., Ltd., a Japanese stock corporation (“Ono”). Onyx and Ono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT #7 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • December 6th, 2023 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This AMENDMENT #7 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("AD Pharma"), a Kentucky limited liability company, having a place of business at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of November 13, 2023.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and Avalon Pharmaceuticals, Inc.License, Development and Commercialization Agreement • September 9th, 2005 • Avalon Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
* The asterisk denotes the confidential portions of this document that have been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
